Research Article

Potential JAK2 Inhibitors from Selected Natural Compounds: A Promising Approach for Complementary Therapy in Cancer Patients

Table 4

Interactions modes between JAK2 catalytic site, top-ranked herbal inhibitors in this study, and JAK2 positive control inhibitor.

Ligand nameHydrogen bond (distance A)Hydrophobic interaction (distance A)

(A) Flavonoids
Orientin (before MD)ASP939 (3.29)NA
Orientin (after MD)Ser936 (3.45); Asp939 (3.82); Gln853 (4.76)NA
Kaempferol 3-rutinoside-4′-glucosideASP939 (4.82); GLN854 (4.06);LYS857 (4.92)
VitexinASP939 (4.70); LYS943 (3.85);NA
IsoquercitrinLEU855 (4.83); SER936 (3.29, 3.33, 2.71); ASP939 (4.09, 3,12)HIS944 (6.11)
Quercetin-3-rhamnosideLEU855 (4.77, 3.52)LYS943 (4.49); HIS944 (6.70)
QuercitrinLEU855 (3.50, 4.74)HIS944 (6.83)
NicotiflorinLYS943 (4.98); SER936 (2.99)LYS943 (4.76)
Kaempferol 7-O-glucosideGLN853 (4.80); ASP939 (3.50); SER936 (2.71); PRO933 (4.81);HIS944 (6.28); LYS943 (5.24)
AstragalinTYR934 (4.87); LEU855 (4.86, 4.51)HIS944 (6.35); LYS943 (4.53); LEU855 (5.96); IZA2001 (8.24)
CynarosideGLN853 (4.81); LYS943 (4.68); TYR934 (4.85, 3.86);NA
Apigenin-7-glucosideLEU855 (3.12); ASP939 (4.04); SER936 (2.99); TYR934 (4.17)NA

(B) Anthraquinones
Pulmatin (before MD)SER936 (2.94, 4.23, 4.04); LEU855 (4.47); ASP939 (3.75, 4.25); LYS857 (4.65)ARG980 (4.09, 6.62)
Pulmatin (after MD)LEU855 (4.33); ASP939 (4.01, 4.52, 4.60)NA
Emodin-8-glucosideASP939 (3.80)TYR934 (4.36); TYR940 (5.20); HIS944 (5.39, 6.58)

(C) Cinnamic acids
Chlorogenic acid (before MD)SER936 (2.96); GLY935 (3.32); ASP939 (3.81); PRO933 (4.78)NA
Chlorogenic acid (after MD)PRO933 (4.07); MET865 (4.62); LEU855 (3.9); LYS943 (4.08)HIS944 (7.1); TYR934 (5.29)
CynarinTYR931 (3.88, 4.50, 4.24); GLU877 (3.93);PRO933 (4.84); VAL878 (4.75)
Rosmarinic acidASP939 (3.60, 4.28, 3.64)NA

(D) Control inhibitor
1ZA (before MD)SER936 (3.22)LEU855 (5.28); IZA2001 (7.29, 6.44, 5.02)
1ZA (after MD)NAALA880 (5.01); LEU932 (4.06); LEU983 (4.93, 5.18); LEU855 (5.24, 5.49)

JAK2, janus-activated kinase 2; 1ZA, 2-TERT-BUTYL-9-FLUORO-3,6-DIHYDRO-7H-BENZ[H]-IMIDAZ[4,5-F] ISOQUINOLINE-7-ONE; pM, picomolar; nM, nanomolar; μM, micromolar.